Protocol Ledger

NCT07003295 · Phase II · RECRUITING

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Interventional Phase II clinical trial protocol NCT07003295 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-08 Enrollment: 20 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07003295
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07003295
Protocol FieldVerified Registry Value
NCT IdentifierNCT07003295
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment20 participants (ESTIMATED)
Registered Start Date2026-07-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI